Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 2
Submit an article Journal homepage
255
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia

Caspar da Cunha-Banga Department of Hematology, Rigshospitalet, Copenhagen, DenmarkCorrespondence[email protected]
View further author information
,
Nikolai S. Kirkbyb Department of Clinical Microbiology, Rigshospitalet, Copenhagen, DenmarkView further author information
,
Lennart Friis-Hansenc Department of Clinical Biochemistry, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark;d Department of Clinical Medicine, Copenhagen University, Copenhagen, DenmarkView further author information
&
Carsten U. Niemanna Department of Hematology, Rigshospitalet, Copenhagen, Denmark;d Department of Clinical Medicine, Copenhagen University, Copenhagen, DenmarkORCID Iconhttps://orcid.org/0000-0001-9880-5242View further author information
ORCID Icon
Pages 503-505 | Received 12 Jul 2021, Accepted 16 Aug 2021, Published online: 02 Nov 2021

References

  • Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137 (23):3165–3173.
  • Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European research initiative on CLL, and CLL campus. Leukemia. 2020;34(9):2354–2363.
  • Harritshøj LH, Gybel-Brask M, Afzal S, et al. Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories. J Clin Microbiol. 2021;59(5):e02596–20.
  • Poljak M, Oštrbenk Valenčak A, Štamol T, et al. Head-to-head comparison of two rapid high-throughput automated electrochemiluminescence immunoassays targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor binding domain. J Clin Virol. 2021;137:104784.
  • Andersen MA, Eriksen CT, Brieghel C, et al. Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. Haematologica. 2018;103(7):e300–e303.
  • Agius R, Brieghel C, Andersen MA, et al. Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nat Commun. 2020;11(1):363.
  • Svanberg R, Janum S, Patten PEM, et al. Targeting the tumor microenvironment in chronic lymphocytic leukemia. Haematologica. 106:2312–2324.
  • Pleyer C, Ali MA, Cohen JI, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia a randomized study by the Swedish CLL group. Blood. 2018;137(2):3701–3707.
  • Waldman RA, Creed M, Sharp K, et al. Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab. J Am Acad Dermatol. 2021;84(4):e197–e198.
  • Thangavadivel S, Zhao Q, Epperla N, et al. Early intervention with lenalidomide in patients with high-risk chronic lymphocytic leukemia. Clin Cancer Res. 2020;26(23):6187–6195.
  • Douglas AP, Trubiano JA, Barr I, et al. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;102(10):e397–e399.
  • Da Cunha-Bang C, Agius R, Kater AP, et al. PreVent-ACaLL short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive imm. Blood. 2019;134(Supplement_1):4304–4304.
  • Jaglowski SM, Jones JA, Nagar V, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126(7):842–850.
  • Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
  • Moustsen-Helms IR, Emborg H-D, Nielsen J, et al. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA covid-19 vaccine in long-term care facility residents and healthcare workers – a Danish cohort study. medRxiv. 2021;3:21252200. https://doi.org/https://doi.org/10.1101/2021.03.08.21252200

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.